Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Lincoln Pharmaceuticals Limited (NSE: LINCOLN), ISIN INE405C01035 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
LINCOLN last traded at ₹520.65 (+2.58%), with a 52-week range of ₹440.00 to ₹770.00 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 49.78%, FIIs 4.55%, DIIs 0.02%, mutual funds 0.00%.
EquiSense Score (ECS): 67/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.